Effects of recombinant human growth hormone administration in obese with relative GHD children

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011267

Enrollment

Unknown

Registered

2017-04-30

Start date

2017-05-10

Completion date

Unknown

Last updated

2017-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity

Interventions

the relative GHD group :rhGH threphy

placebo group:placebo

Eligibility

Sex/Gender

All

Age

3 Years to 19 Years

Inclusion criteria

Inclusion criteria: the body mass index(BMI) is greater than 95 percent of normal weight children

Exclusion criteria

Exclusion criteria: (1) secondary obesity(e.g. hypothyroidism, Cushing's disease, hypothalamic obesity); (2) children who ever have alcohol intake, smoked or used drugs which may influence blood pressure, liver function, glucose, lipid metabolism or weight; (3) children who have suffered from hypothalamus diseases, pituitary diseases, diabetes mellitus, systemic illness, chromosome abnormalities or all sorts of syndromes; (4) those who have hepatitis B, hepatitis C or any other liver diseases which can lead to liver damage.

Design outcomes

Primary

Measure	Time frame
GH stimulating tests;IGF-1;thyroid function;Liver function;lipid;Fasting insulin;FBG;hypothalamic-pituitary;	—

Countries

China

Contacts

Public ContactJiang Xue

The Second Hospital of Shandong University

sdxj69@163.com+86 15153169127

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026